Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alpharma, Inc.
U.S. FDA grants approval for glyburide/metformin HCL tablets
August 10th, 2005
Alpharma, Inc., (ALO) announced that the U.S. Food and Drug Administration has granted final approval for the company's abbreviated new drug application (ANDA) for glyburide/metformin HCl tablets in the following dosages: 1.25 mg/250 mg; 2.5 mg/500 mg; and 5 mg/500 mg. Alpharma's glyburide/metformin HCl Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucovance Tablets, a product indicated as an adjunct to diet and exercise in the treatment of type 2 diabetes. Glucovance Tablet sales in 2004 were approximately $270 million. Glucovance is a trademark of Lipha Corporation. Alpharma is presently active in more...
Source: Biotech Week (2005-08-10)
|
